

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jun 2026

Comparison of the Effectiveness of noradrenaline with the combination of octreotide and midodrine in the treatment of hepatorenal syndrome type 1

Protocol summary

Study aim

Comparison of the effectiveness of noradrenaline treatment against combined treatment of midodrine and octreotide in hepatorenal syndrome

Design

Clinical trial with control group, with parallel groups, double-blind, randomized by randomized block method

Settings and conduct

This study was designed in Sayad Hospital in Gorgan. In this double-blind study (patients and researchers), patients were randomized into two intervention groups (patients suspected of HRS on noradrenaline treatment with an initial dose of 1 mg per hour with continuous injection and then in order to achieve the minimum output urine output of at least 400 ml per 12 hours, gradually increasing to a maximum dose of 4 mg/hour) and the control group (receive midodrine orally with an initial dose of 7.5 mg three times a day, with a dose increase to a maximum of 12.5 mg three times a day) once daily, with subcutaneous octreotide: starting dose of 100 µg three times daily and up to 200 µg three times daily, both groups 20 to 40 g/day will receive albumin intravenously) are divided.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age between 18 and 70 years/ diagnosis of hepatorenal syndrome based on the revised diagnostic criteria of HRS, 2007: cirrhosis + ascites + increased serum creatinine level (more than 1.5 mg/dL) and failure to improve within 48 hours with diuretic discontinuation and Volume increase with albumin/no use of nephrotoxic drugs/no kidney parenchymal disease or obstructive uropathy in laboratory and ultrasound evaluation/Doubling of creatinine level to more than 2.5 mg/dL in 2 weeks or less/ Exclusion criteria: History of coronary disease and evidence of ventricular arrhythmia or cardiomyopathy

Intervention groups

Group 1/ midodrine, octreotide and albumin and group 2/ intervention group with noradrenaline and albumin treatment.

Main outcome variables

Treatment of hepatorenal syndrome

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230228057568N1**

Registration date: **2023-03-05, 1401/12/14**

Registration timing: **prospective**

Last update: **2023-03-05, 1401/12/14**

Update count: **0**

Registration date

2023-03-05, 1401/12/14

Registrant information

Name

Maryam Maqsoudloo

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 17 3262 5346

Email address

maryamm.maqsoudl1367@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-03-21, 1402/01/01

Expected recruitment end date

2023-09-22, 1402/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the Effectiveness of noradrenaline with the combination of octreotide and midodrine in the treatment of hepatorenal syndrome type 1

Public title

Comparison of noradrenaline with the combination of octreotide and midodrine in the treatment of hepatorenal syndrome type 1

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Diagnosis based on modified HRS diagnostic criteria in 2007: Cirrhosis with ascites and increased serum creatinine level (>1.5 mg/dL) with non-recovery up to 48 hours after diuretic discontinuation and volume increase with albumin
Absence of shock
Not receiving nephrotoxic drugs
Absence of kidney parenchymal disease or obstructive uropathy in laboratory and ultrasound assessment
Doubling of creatinine level to more than 2.5 mg/dL in 2 weeks or less

Exclusion criteria:

History of coronary disease and evidence of ventricular arrhythmia or cardiomyopathy obtained based on history taking, assessment of risk factors, physical examination, echocardiography and radiography.

Age

From **18 years** old to **70 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization method: In order to randomize samples, we use a block method with quadrilateral blocks. In this way, one of the following blocks is first selected by accident (for example, with a dice), and according to the order in which those samples are We assign two groups (A for the group receiving Noradrenaline and B for the Standard treatment group). For example, if block 3 is selected and the first one is assigned to the group receiving the Noradrenaline, and the second and third samples will be allocated to the Standard treatment recipient group, the fourth will be assigned to the group receiving the Noradrenaline. Then for four samples, again, a block will be randomly selected. We will allocate

it to it and this process will proceed to the end of the sampling.

Blinding (investigator's opinion)

Double blinded

Blinding description

The study is double-blind. In this way, all the patients and the student facilitator evaluating the designed interventions (internal medicine assistant, project manager) in the study or the outcomes after the project (internal medicine assistant and nephrology specialist) will not know about the study groups.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Golestan University of medical sciences

Street address

Golestan University of Medical Sciences Research Office, The beginning of Shast Kolah Road, Hirkan Blvd, Basij Square

City

Gorgan

Province

Golestan

Postal code

4917761551

Approval date

2022-11-27, 1401/09/06

Ethics committee reference number

IR.GOUMS.REC.1401.374

Health conditions studied**1****Description of health condition studied**

Hepatorenal Syndrome

ICD-10 code

K76.7

ICD-10 code description

Hepatorenal syndrome

Primary outcomes**1****Description**

Reduction of serum creatinine level below 1.5 mg

Timepoint

Before the intervention and days 1, 3, 7 and 14

Method of measurement

Blood and urine samples

2

Description

Increase in 4-hour urine output above 200 ml

Timepoint

Before the intervention and days 1, 3, 7 and 14

Method of measurement

Blood and urine samples

3

Description

Statistically significant improvement in serum creatinine and sodium levels.

Timepoint

Before the intervention and days 1, 3, 7 and 14

Method of measurement

Blood and urine samples

Secondary outcomes

1

Description

Treatment of hepatorenal syndrome and mortality rate

Timepoint

Beginning and end of day 14

Method of measurement

Blood/urine samples and bedside examination

Intervention groups

1

Description

Intervention group: Patients receiving Noradrenaline and Albumin treatment/ In this group, patients with Hepatorenal Syndrome were treated with Noradrenaline at an initial dose of 1 mg/h with continuous injection and then gradually increased to a maximum dose of 4 mg/h in order to achieve a minimum urine output of at least 400 ml per 12 hours + Receiving Albumin on the first day of 1 gram per kilogram of body weight and then 20 to 40 grams per day intravenously for up to 14 days/ basic and clinical and laboratory information in both groups at the beginning and then on days 1, 3, 7, and 14 and the maximum time Readmission will be checked.

Category

Treatment - Drugs

2

Description

Control group: standard treatment of patients with Midodrine, Octreotide and albumin (receive Midodrine orally with an initial dose of 7.5 mg three times a day, with a dose increase up to a maximum of 12.5 mg three times a day, together with Octreotide subcutaneously:

initial dose 100 µg three times a day and up to 200 µg three times a day +Receiving Albumin on the first day of 1 gram per kilogram of body weight and then 20 to 40 grams per day intravenously for up to 14 days / basic and clinical and laboratory information in both groups at the beginning and then on days 1, 3, 7, and 14 and the maximum time Readmission will be checked.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Sayad Shirazi Hospital

Full name of responsible person

Dr. Saeed Amir Khanlou

Street address

Shahid Sayad Shirazi Hospital, Shahid Sayad Shirazi Boulevard, Bahnar Square, Gorgan

City

Gorgan

Province

Golestan

Postal code

49178677439

Phone

+98 17 3220 2154

Email

Sayyadlib@goums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Gorgan University of Medical Sciences

Full name of responsible person

Dr Mohammadreza Honarvar

Street address

Ethics Committee of the Vice Chancellor for Research and Technology, 3rd Floor, School of Dentistry, Golestan University of Medical Sciences, Shast Kola Road, Gorgan, Iran

City

Gorgan

Province

Golestan

Postal code

4934174523

Phone

+98 17 3245 0021

Email

tahghighat.g@goums.ac.ir

Grant name

Gorgan University of Medical Sciences

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes
Title of funding source
Gorgan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Gorgan University of Medical Sciences
Full name of responsible person
Maryam Maqsoodloo
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
Number 11, Aseman building, Shahriar Alley 5,
Shahriar Blvd, Shahryar town
City
Gorgan
Province
Golestan
Postal code
49178677439
Phone
+98 17 3262 5346
Fax
Email
maryamm.maqsoudl1367@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Gorgan University of Medical Sciences
Full name of responsible person
Dr. Saeed Amirkhanlou
Position
Associate Professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Nephrology's Clinic and Obstetrics and Gynecology
Department, 2nd floor, Shahid Sayad Shirazi Hospital,
Sayad Shirazi Blvd., Bahonar Square, Gorgan, Iran
City

Gorgan
Province
Golestan
Postal code
4915663158
Phone
+98 17 3226 1175
Email
drsam74ir@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Gorgan University of Medical Sciences
Full name of responsible person
Maryam Maqsoodloo
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
Number 11, Aseman building, Shahriar Alley 5,
Shahriar Blvd, Shahryar town
City
Gorgan
Province
Golestan
Postal code
49178677439
Phone
+98 17 3262 5346
Fax
Email
maryamm.maqsoudl1367@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Not applicable
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
All data is potentially shareable after de-identifying
individuals
When the data will become available and for how long
Access period starts 6 months after the results are
published
To whom data/document is available

It will be available to researchers working in academic and scientific institutions

Under which criteria data/document could be used

There are no restrictions to perform statistical analyzes and access to data and documents. elated additional documents such as study protocol, data analysis program, etc. will also be shared.

From where data/document is obtainable

Dr. Maryam Maqsoodlou: internal resident/ phone number: 09113759570/ Email: maryamm.maqsoodl1367.com/ postal code:

4913983794/ address: Number 11, Aseman building, Shahriar Alley 5, Shahriar Blvd, Shahryar town, Gorgan city

What processes are involved for a request to access data/document

The applicant should provide his / her study file and the purpose of receiving the data in the form of an email with his / her research file (research plan), then after 3 months the file will be provided to the person

Comments